Remove 2025 Remove Diabetes Remove Strokes
article thumbnail

Abstract WP48: Potential Role of Diabetes-Associated Hyperamylinemia in Stroke

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page AWP48-AWP48, February 1, 2025. Introduction:Type-2 diabetes increases the risk of stroke; however, the mechanisms remain incompletely understood. Treatment with sEHI reduced vascular amylin deposition (198.6

article thumbnail

Abstract TP31: Intranasal treatment targeting the brain endothelin system attenuates cognitive decline in diabetic rats after ischemic injury

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ATP31-ATP31, February 1, 2025. Diabetes increases the risk of Vascular Contributions to Cognitive Impairment&Dementia (VCID) and stroke further amplifies this effect. Diabetes also dysregulates the Endothelin (ET) system.

article thumbnail

Abstract TP350: The Effect of Type 2 Diabetes on the Transcriptome of Immune Cells in the Bone Marrow in Response to Ischemic Stroke

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ATP350-ATP350, February 1, 2025. Type 2 diabetes mellitus (T2DM) induces chronic inflammation, which can worsen the secondary injury following ischemic stroke.

Strokes 40
article thumbnail

Abstract TP9: Hemorrhagic Transformation in Acute Ischemic Stroke and Diabetes: Is it Different between Alteplase and Tenecteplase?

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ATP9-ATP9, February 1, 2025. Introduction:Tenecteplase (TNK) is now an accepted alternative to Alteplase (ALT) for intravenous thrombolysis (IVT) in acute ischemic stroke (AIS). Time to IVT was grouped as ultra-early (0-90 min), early (91-180 min), and late (181-270 min).

article thumbnail

Impact of Conventional Stroke Risk Factors on Early- and Late-Onset Ischemic Stroke: A Mendelian Randomization Study

Stroke Journal

Stroke, Volume 56, Issue 3 , Page 640-648, March 1, 2025. These divergent trends are at least partially attributable not only to diverging trends in stroke risk factors but may also be due to differences in the impact of stroke risk factors at different ages. versus 1.03;P=0.008).

article thumbnail

Abstract TP136: STRACK: A Continuum of Stroke Care, Improving Post-Stroke and Cardiometabolic Patient Outcomes

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page ATP136-ATP136, February 1, 2025. Once these post-stroke patients have been identified, they are given a personalized monitoring plan depending on the individuals risk factors, the personalized care and rehabilitation plans are tracked and followed.

Strokes 40
article thumbnail

Abstract 51: Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Prevention of Stroke among Patients with Type 2 Diabetes Mellitus, Heart Failure, or Obesity: A Meta-Analysis of 12 Randomized Controlled Trials.

Stroke Journal

Stroke, Volume 56, Issue Suppl_1 , Page A51-A51, February 1, 2025. Background:Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown a reduction in major adverse cardiovascular events (MACE) among patients with type 2 diabetes mellitus (T2DM). 0.96),P<0.001), and nonfatal stroke by 13% (OR, 0.87(95%CI: